<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fever in children with chemotherapy-induced neutropenia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fever in children with chemotherapy-induced neutropenia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fever in children with chemotherapy-induced neutropenia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nabil M Ahmed, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patricia M Flynn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David G Poplack, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection is a major cause of morbidity and mortality in patients with cancer. Fever may be the first manifestation of a life-threatening infection, particularly during periods of neutropenia.
        </p>
        <p>
         Evaluation and management of fever in children with chemotherapy-induced neutropenia are reviewed here. The types of infections and management of fever in the child with other forms of neutropenia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">
          "Evaluation of children with non-chemotherapy-induced neutropenia and fever"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6059.html" rel="external">
          "Management of children with non-chemotherapy-induced neutropenia and fever"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23804302">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutropenia
         </strong>
         – For the purposes of management of fever in children with cancer or hematopoietic cell transplant, neutropenia is defined as an absolute neutrophil count (ANC) &lt;500 cells/microL or an ANC that is expected to decrease to &lt;500 cells/microL during the next 48 hours [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ANC is calculated using the following formula (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         ):
        </p>
        <p>
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p class="bulletIndent2">
           <span class="glyph">
            •
           </span>
           ANC = total white blood cell count (cells/microL) x (percent polymorphonuclear cells [PMNs] + percent bands) ÷ 100
          </p>
         </div>
        </div>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fever
         </strong>
         – In neutropenic patients, fever is defined as a single oral temperature ≥38.3°C (101°F), a temperature ≥38°C (100.4°F) for longer than one hour, or two elevations &gt;38°C (100.4°F) during a 12-hour period [
         <a href="#rid1">
          1,3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rectal temperature measurement should be avoided in neutropenic patients to avoid the possibility of introducing infection through mucosal trauma. Oral temperature measurement is preferred to other nonrectal sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An axillary temperature is acceptable if the patient is unable to use an oral thermometer. Many electronic thermometers automatically adjust for oral, axillary, or rectal location If the electronic thermometer automatically adjusts for location, the thresholds stated above for oral temperature measurements should be used. If the axillary thermometer does not automatically adjust, some centers consider fever as a single axillary temperature of ≥37.7°C (99.9°F) or axillary temperature ≥37.4°C (99.4°F) for longer than one hour [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H614955913">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fever occurs in approximately one-third of neutropenic episodes in children with cancer or hematopoietic cell transplantation (range 10 to 60 percent) [
         <a href="#rid6">
          6
         </a>
         ]. The approximate rate of occurrence is 0.76 episodes per every 30 days of neutropenia.
        </p>
        <p>
        </p>
        <p>
         In the United States between 2007 and 2014, the rate of hospitalizations for fever and neutropenia in pediatric cancer patients ranged from 13 to 18 per 100,000 population and increased over time [
         <a href="#rid7">
          7
         </a>
         ]. The median length of stay was four to five days. The overall mortality rate was 0.75 percent. Sepsis, pneumonia, meningitis, and mycosis were the comorbidities most frequently associated with mortality.
        </p>
        <p class="headingAnchor" id="H1658196021">
         <span class="h1">
          FEVER AND INFECTION IN CHILDREN WITH CANCER
         </span>
        </p>
        <p class="headingAnchor" id="H3958275139">
         <span class="h2">
          Clinical presentation and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fever is often the only sign of occult infection in the neutropenic host [
         <a href="#rid1">
          1
         </a>
         ]. However, serious infection may occur in the absence of fever or neutropenia. Children with infection who are receiving glucocorticoids may present with a lower and/or intermittent temperature elevation.
        </p>
        <p>
         Serious infection must be considered and promptly treated in pediatric cancer patients or hematopoietic cell transplant (HCT) recipients who are [
         <a href="#rid1">
          1,2,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Febrile and neutropenic
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Febrile and not neutropenic
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Afebrile and neutropenic with signs of infection or clinical deterioration (eg, hypothermia, hypotension, listlessness, confusion)
        </p>
        <p>
        </p>
        <p>
         Risk factors for serious infection in children with cancer or HCT recipients include [
         <a href="#rid1">
          1,9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chemotherapy-induced neutropenia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central venous catheters (whether or not the child is neutropenic); the risk of serious bacterial infection is lower with totally implantable catheters (eg, mediports, portacaths) than with tunneled external catheters or peripherally inserted catheters [
         <a href="#rid8">
          8,10
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Functional neutropenia" (eg, hematologic malignancies that impair phagocytosis and killing of pathogens, even if the absolute neutrophil count is normal)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breakdown of skin and mucosal barriers (eg, mucositis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered humoral and cellular immunity, particularly if neutropenia is anticipated to last for &gt;7 days [
         <a href="#rid11">
          11
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Risk factors for invasive fungal infection are discussed below. (See
         <a class="local">
          'Addition of antifungal therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H182637660">
         <span class="h2">
          Infectious causes of fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children with chemotherapy-induced neutropenia, the rate of documented infection ranges between 10 and 40 percent [
         <a href="#rid6">
          6,12-17
         </a>
         ]. The most common documented infection is bacteremia, which accounts for approximately 20 to 50 percent; the proportion varies with the underlying malignancy and the institution [
         <a href="#rid13">
          13,14,18-22
         </a>
         ]. Other sites of infection include the gastrointestinal tract (related to oral or intestinal mucositis), upper and lower respiratory tract, urinary tract, and skin and soft tissues [
         <a href="#rid12">
          12,23,24
         </a>
         ].
        </p>
        <p>
         Gram-positive and gram-negative organisms are frequently isolated from the blood in children with fever and chemotherapy-induced neutropenia [
         <a href="#rid6">
          6,14,25
         </a>
         ]. The frequency of isolation of specific organisms varies from institution to institution. However, with increased use of prophylactic antimicrobials and indwelling venous catheters, there has been a general shift toward dominance of gram-positive organisms [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gram-positive bacteria
         </strong>
         – The most common gram-positive pathogens are coagulase-negative staphylococci, viridans streptococci, and
         <em>
          Staphylococcus aureus
         </em>
         (including methicillin-resistant
         <em>
          S. aureus
         </em>
         ) [
         <a href="#rid6">
          6,14,17,20,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gram-negative bacteria
         </strong>
         – Aerobic gram-negative bacilli account for approximately one-third to one-half of bacteremic episodes, with
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Klebsiella
         </em>
         spp,
         <em>
          Pseudomonas
         </em>
         spp,
         <em>
          Acinetobacter
         </em>
         spp, and
         <em>
          Enterobacter
         </em>
         spp among the more common isolates [
         <a href="#rid6">
          6,14,17,20,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fungi
         </strong>
         – Fungi, typically
         <em>
          Candida
         </em>
         spp, are more likely to be recovered after prolonged courses of broad-spectrum antibiotics but occasionally may be the primary pathogen [
         <a href="#rid6">
          6
         </a>
         ]. Other potential fungal organisms include
         <em>
          Aspergillus
         </em>
         spp, Zygomycetes, and
         <em>
          Cryptococcus
         </em>
         spp [
         <a href="#rid28">
          28,29
         </a>
         ].
         <em>
          Fusarium
         </em>
         spp and dematiaceous fungal infections also have been increasingly recognized in these hosts [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The increasing use of antifungal prophylaxis has shifted the distribution of fungal isolates away from
         <em>
          Candida
         </em>
         and
         <em>
          Aspergillus
         </em>
         spp toward more unusual mold infections [
         <a href="#rid32">
          32
         </a>
         ]. This is particularly true in HCT recipients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viruses
         </strong>
         – Respiratory viruses, herpes simplex virus, and varicella-zoster virus are relatively common viral causes of infection in children with fever and chemotherapy-induced neutropenia [
         <a href="#rid14">
          14,33-40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1204748144">
         <span class="h2">
          Noninfectious causes of fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Noninfectious causes of fever in children with cancer include drug fever, cancer-related fever, deep vein thrombosis, pulmonary embolus, transfusion reaction, and dysautonomia (in children with central nervous system disease).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection is a major cause of morbidity and mortality in patients with fever and chemotherapy-induced neutropenia. Rapid and thorough evaluation is critical so that empiric antimicrobial therapy can be administered promptly (as soon as possible and always within 60 minutes of triage). (See
         <a class="local">
          'Prompt initiation of antimicrobial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H176622907">
         <span class="h2">
          History and examination
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – Important aspects of the history in a child with fever and neutropenia include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New site-specific symptoms of localized infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antimicrobial prophylaxis (may decrease the risk of infection and modify the choice of empiric antimicrobial therapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infection exposures
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recent documented infections or colonization (may affect the choice of empiric therapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Underlying comorbid conditions, such as diabetes or recent surgery (increase the risk of infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Previous chemotherapy, agents used, and the stage of therapy (to anticipate the length of the neutropenic episode)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Current medications, including glucocorticoids and immunosuppressive agents for children with hematopoietic cell transplantation (HCT) (may extend the risk of serious infection beyond the duration of neutropenia)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravascular catheters or other devices (see
         <a class="local">
          'Clinical presentation and risk factors'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concomitant noninfectious cause of fever (eg, receipt of blood products) (see
         <a class="local">
          'Noninfectious causes of fever'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vaccination history (affects the infections to be considered in the differential diagnosis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – The physical examination should be thorough and focused on the most common sites of infection (listed below) [
         <a href="#rid1">
          1
         </a>
         ]. In children with neutropenia, clinical findings of inflammation may be subtle; mild erythema or tenderness should not be ignored. The physical examination should be repeated at least daily. Signs of inflammation may become evident as the neutrophil count recovers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Important aspects of the physical examination in children with fever and chemotherapy-induced neutropenia include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal vital signs (eg, hypotension, tachycardia); wide pulse pressure may indicate septic shock; tachycardia out of proportion to the degree of fever or tachycardia that persists despite defervescence may be a sign of early septic shock (even without hypotension)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin (looking for poor perfusion; slow capillary refill and signs of localized infection, especially in skin folds, areas surrounding nail beds, central venous catheter exit sites and subcutaneous tunnel [if present]; and sites of bone marrow aspiration and lumbar puncture)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sinuses
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oropharynx, including the gums, which may be a source for bacteremia [
         <a href="#rid41">
          41
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lungs (particularly for signs of pneumonia [eg tachypnea, crackles, increased work of breathing])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abdomen
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perineum, particularly the perianal and labial regions; digital rectal examination should be avoided
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mental status changes
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3719290787">
         <span class="h2">
          Routine laboratory and imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The laboratory evaluation for the child with fever and neutropenia should include (at minimum) [
         <a href="#rid1">
          1,42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential and platelet count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrolytes, creatinine, and blood urea nitrogen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver transaminases and total bilirubin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood cultures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral panel, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza as indicated by local epidemiology and/or compatible symptoms
        </p>
        <p>
        </p>
        <p>
         Additional cultures, molecular diagnostic assays, and/or imaging should be obtained if localized infection is suspected. (See
         <a class="local">
          'Additional studies as indicated'
         </a>
         below.)
        </p>
        <p>
         Treatment should be initiated as soon as possible after blood cultures are obtained and always within 60 minutes of triage. It should not be delayed while waiting for results or performing additional studies. (See
         <a class="local">
          'Prompt initiation of antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         Although we do not routinely obtain them, in addition to the tests listed above, some experts also include C-reactive protein (CRP), lactate, and urinalysis in children &lt;5 years as part of the initial evaluation [
         <a href="#rid2">
          2
         </a>
         ]. CRP has been used in risk categorization strategies in several pediatric studies [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood cultures
         </strong>
         – Blood cultures should be obtained without delay. Blood cultures should be taken from each lumen of the central catheter when such access is available [
         <a href="#rid42">
          42,45
         </a>
         ]. In observational studies, approximately 30 to 40 percent of positive cultures from multiple lumen catheters were positive from only one lumen [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also obtain peripheral blood cultures. Culturing blood from both peripheral and central sites helps to distinguish true bacteremia from infection related to the catheter and to guide decisions about catheter removal [
         <a href="#rid48">
          48
         </a>
         ]. Peripheral cultures increase the identification of true bacteremia. In a meta-analysis of observational studies, 13 percent of bloodstream infections in patients with cancer were detected only in the peripheral culture [
         <a href="#rid49">
          49
         </a>
         ]. This potential increased yield is balanced against pain and potential isolation of contaminants [
         <a href="#rid42">
          42
         </a>
         ]. Diagnosis of intravascular catheter-related infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Obtaining more than one blood culture is helpful in the interpretation of blood culture results. If coagulase-negative staphylococci are isolated from two or more blood cultures, true bacteremia is more likely than contamination of the specimen, which may be reflected by a single positive blood culture.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Repeat blood cultures are discussed below. (See
         <a class="local">
          'Reevaluation during treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urine culture
         </strong>
         – We obtain urine cultures in children with urinary symptoms, history of urinary tract infection (UTI), and/or urinary tract abnormalities. Other experts routinely obtain urine cultures in females or young children who may not complain of urinary tract symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Urinalysis should not be used to determine the need for urine culture. In a small observational study of children with UTI, pyuria was found in only one of 23 neutropenic patients, compared with 21 of 31 without neutropenia [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3636206272">
         <span class="h2">
          Additional studies as indicated
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional studies should be obtained as clinically indicated for signs or symptoms of localized infection. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory signs and symptoms – Respiratory virus molecular analysis (including for SARS-CoV-2 and seasonal respiratory viruses [eg, influenza, respiratory syncytial virus] as indicated by local epidemiology and/or compatible symptoms, if not already obtained [
         <a href="#rid51">
          51
         </a>
         ]) or culture of nasopharyngeal wash [
         <a href="#rid38">
          38
         </a>
         ] and chest radiograph [
         <a href="#rid42">
          42,52,53
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children with respiratory signs and symptoms, chest radiographs without infiltrates should be interpreted with caution. The appearance of infiltrates may be delayed until neutrophil counts are recovering.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any site with purulent drainage – Gram stain and culture
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain and diarrhea (suspected neutropenic enterocolitis [typhlitis]) – Abdominal ultrasonography and anaerobic blood culture
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with HCT – Testing for
         <em>
          Clostridioides difficile
         </em>
         and viral pathogens (see
         <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">
          "Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Etiologic diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Clinical features and diagnosis", section on 'Testing for C. difficile'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with ≥3 loose bowel movements per day without a known source – Testing for
         <em>
          C. difficile
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Clinical features and diagnosis", section on 'Testing for C. difficile'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered mental status or meningeal signs – Lumbar puncture; platelet transfusion may be necessary before lumbar puncture in patients with neutropenia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin and soft tissue lesions – Aspiration and/or biopsy for microbial staining, cultures and other microbiologic studies for suspected pathogens, histology, and cytology [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1031528318">
         <span class="h1">
          REEVALUATION DURING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with fever and chemotherapy-induced neutropenia should be reevaluated at least once daily during antimicrobial therapy. The evaluation typically includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review of systems for infection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination with particular attention to the sites most frequently infected (see
         <a class="local">
          'History and examination'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential and platelet count daily during hospital admission
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children who remain febrile after initiation of empiric antimicrobial therapy, repeat blood cultures once daily for the next two days and then if there is deterioration of clinical condition [
         <a href="#rid1">
          1,16,54
         </a>
         ]; some experts recommend daily blood cultures regardless of clinical status
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat blood culture for recurrent fever (after being afebrile for ≥24 hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cultures and/or imaging for any suspected sites of infection
        </p>
        <p>
        </p>
        <p>
         Additional evaluation for children with clinical worsening or instability is discussed below. (See
         <a class="local">
          'Clinical worsening or instability'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1780452581">
         <span class="h1">
          RISK STRATIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with fever and neutropenia can be categorized as high- and low-risk for severe infection or complications based upon presenting signs and symptoms, absolute neutrophil count (ANC), underlying cancer, anticipated duration of neutropenia (varies with type of chemotherapy), and medical comorbidities [
         <a href="#rid1">
          1,42
         </a>
         ].
        </p>
        <p>
         Several risk stratification strategies that incorporate one or more of these factors have been validated in children and are used at various institutions [
         <a href="#rid13">
          13,43,44,55-57
         </a>
         ]. The choice of strategy varies by institution [
         <a href="#rid42">
          42,58
         </a>
         ]. We provide some general guidelines below  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk
         </strong>
         – High-risk patients have an increased risk of severe infection or complications and should be admitted to the hospital for empiric antimicrobial therapy. (See
         <a class="local">
          'Prompt initiation of antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We consider patients with any of the following to be high risk  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neutropenia (ANC &lt;500 cells/microL) anticipated to last &gt;7 days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The relative risk of infection is related to both the degree and duration of neutropenia. An increased risk becomes apparent at an ANC &lt;1000 cells/microL, is greater at an ANC &lt;500 cells/microL, and greatest at an ANC ≤100 cells/microL (profound neutropenia) [
         <a href="#rid6">
          6,59
         </a>
         ]. Patients with neutropenia projected to last for more than seven days also are at a higher risk of infection than are those with neutropenia of shorter duration [
         <a href="#rid11">
          11,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Formal studies to clearly differentiate between patients with an ANC &lt;500 cells/microL and ANC ≤100 cells/microL are lacking. Our ANC threshold for high-risk differs from that in the 2010 Infectious Diseases Society of America guidelines (≤100 cells/microL anticipated to last &gt;7 days) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence of hepatic insufficiency (aminotransferase levels &gt;5 times normal values)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence of renal insufficiency (creatinine clearance &lt;30 mL/min)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Comorbid medical problems including, but not limited to:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hemodynamic instability
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oral or gastrointestinal mucositis that interferes with swallowing or causes diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Gastrointestinal symptoms, including abdominal pain, nausea, vomiting, or diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         New-onset neurologic or mental status changes
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Signs of intravascular catheter infection, particularly catheter tunnel infection (eg, erythema, swelling, and/or tenderness at the insertion site, rigors or chills associated with catheter flushing or infusion)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         New pulmonary infiltrate or hypoxemia or underlying chronic lung disease
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         New findings or symptoms associated with localized infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infants with acute lymphoblastic leukemia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with acute myeloid leukemia [
         <a href="#rid61">
          61
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients within 30 days of hematopoietic cell transplant (HCT); some centers extend this period to within 100 days of HCT
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-risk
         </strong>
         — Low-risk patients are those with all of the following  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neutropenia expected to resolve within seven days (ie, neutrophil count increasing)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stable and adequate hepatic and renal function
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No active comorbidities (eg, hemodynamic instability, mucositis, gastrointestinal symptoms)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children initially assessed to be at low risk can move into the high-risk category after initial presentation if they develop a high-risk feature.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Carefully selected low-risk patients may be candidates for oral empiric therapy or outpatient treatment. (See
         <a class="local">
          'Empiric therapy for low-risk patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3848500842">
         <span class="h1">
          PROMPT INITIATION OF ANTIMICROBIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt initiation (ie, as soon as possible and always within 60 minutes of triage) of empiric-broad spectrum antibiotics is the cornerstone of therapy for patients with fever and chemotherapy-induced neutropenia. In an observational study in pediatric cancer patients with fever and neutropenia, receipt of antibiotics within 60 minutes of presentation was associated with decreased rates of consultation for or admission to the intensive care unit [
         <a href="#rid62">
          62
         </a>
         ]. Conversely, administration of antibiotic therapy more than 60 minutes after presentation has been associated with increased adverse outcomes and length of stay [
         <a href="#rid63">
          63-65
         </a>
         ].
        </p>
        <p>
         Our approach to the selection of empiric antibiotic therapy in children with fever and chemotherapy-induced neutropenia, detailed in the sections below, is generally consistent with the recommendations of expert guidelines  (
         <a class="graphic graphic_table graphicRef120292 graphicRef120756" href="/z/d/graphic/120292.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid1">
          1,2,42
         </a>
         ]. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H718865719">
         <span class="h1">
          EMPIRIC THERAPY FOR HIGH-RISK PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3145760133">
         <span class="h2">
          Broad-spectrum monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with fever and chemotherapy-induced neutropenia who are at high risk for severe infection or complications  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ) should be hospitalized for empiric intravenous (IV) antimicrobial therapy. The initial empiric regimen is individualized (eg, for drug allergies, organ dysfunction, antimicrobial prophylaxis) [
         <a href="#rid1">
          1,2,42,66
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For high-risk children with fever and chemotherapy-induced neutropenia who are clinically stable and in whom there is no suspicion of resistant infection (eg, methicillin-resistant
         <em>
          S. aureus
         </em>
         [MRSA]), we recommend initial broad-spectrum monotherapy with an antipseudomonal beta-lactam agent (eg,
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         [doses are provided below]) to provide activity against the pathogens that are associated with serious or life-threatening infections in neutropenic patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For high-risk children with fever and neutropenia following hematopoietic cell transplantation (HCT),
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         is preferred to
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ]. In observational studies, the use of antibiotics with anaerobic activity (eg, meropenem, piperacillin-tazobactam) eradicates beneficial gut microbiota and has been associated with increased rates of graft-versus-host disease and overall mortality [
         <a href="#rid68">
          68-71
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          Ceftazidime
         </a>
         is no longer recommended for empiric monotherapy in high-risk patients because of increased resistance among many gram-negative pathogens and weak activity against viridans streptococci.
        </p>
        <p>
         Combination therapy is reserved for children with clear indications for additional activity against gram-positive, gram-negative, or anaerobic bacteria (eg, hemodynamic instability, localized infection, concern for resistant pathogens)  (
         <a class="graphic graphic_table graphicRef120756" href="/z/d/graphic/120756.html" rel="external">
          table 2B
         </a>
         ) [
         <a href="#rid1">
          1,2,42
         </a>
         ]. (See
         <a class="local">
          'Limited indications for combination therapy'
         </a>
         below.)
        </p>
        <p>
         The doses for antimicrobials used for initial empiric therapy in patients with normal renal and hepatic function are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cefepime – 50 mg/kg IV every 8 hours up to a maximum of 2 g per dose,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meropenem (for children ≥3 months of age),
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For noncentral nervous system infections – 20 mg/kg IV every 8 hours up to a maximum of 1 g per dose
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For central nervous system infection – 40 mg/kg IV every 8 hours up to a maximum of 2 g/dose
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Piperacillin-tazobactam (dosed according to the
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         component)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &lt;2 months of age – 80 mg/kg IV every 6 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         2 to 9 months of age – 80 mg/kg IV every 8 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &gt;9 months
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &lt;40 kg – 100 mg/kg IV every 6 to 8 hours (maximum of 16 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight ≥40 kg – 3 g IV every 6 hours; this regimen aims to optimize drug levels for organisms with higher minimum inhibitory concentrations [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Most patients with penicillin allergy can tolerate cephalosporins. However, those with a history of immediate-type penicillin allergy  (
         <a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">
          table 3
         </a>
         ) or serious delayed reactions  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 4
         </a>
         ) should not receive cephalosporins or carbapenems. Although carbapenems often are avoided in patients with penicillin allergy because of potential cross reactivity, few studies describing the cross-reactivity between penicillin and carbapenems have been performed [
         <a href="#rid73">
          73
         </a>
         ]. Appropriate alternatives for children with immediate-type hypersensitivity reaction to penicillin include either
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12949" href="/z/d/drug information/12949.html" rel="external">
          aztreonam
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions"
         </a>
         .)
        </p>
        <p>
         Monotherapy with
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         provides activity against a broad spectrum of potential pathogens, particularly those that are associated with serious or life-threatening infections in neutropenic patients. (See
         <a class="local">
          'Infectious causes of fever'
         </a>
         above.)
        </p>
        <p>
         In randomized trials and systematic reviews, empiric monotherapy with these agents is as efficacious as combination therapy but with fewer adverse events [
         <a href="#rid74">
          74-76
         </a>
         ]. In the systematic review that was limited to children, treatment failure rates, overall mortality, and infection-related mortality were similar with monotherapy and aminoglycoside-containing combination therapy [
         <a href="#rid74">
          74
         </a>
         ]. Similar rates of treatment failure, rates of infection-related mortality, and duration of fever were observed in direct comparisons of monotherapy with fourth generation cephalosporins (eg,
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ) and monotherapy with
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         . In a subsequent randomized trial, the efficacy and safety of piperacillin-tazobactam and
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         were similar [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Aminoglycoside monotherapy is not recommended as initial empiric therapy because of the rapid development of resistance. In addition, aminoglycosides are associated with oto-and nephrotoxicity and their use requires monitoring of drug levels and kidney function [
         <a href="#rid78">
          78
         </a>
         ]. They may be added to initial therapy in certain patients with complications. (See
         <a class="local">
          'Limited indications for combination therapy'
         </a>
         below.)
        </p>
        <p>
         The use of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         monotherapy for initial empiric therapy of febrile neutropenia is limited to reduce the risk of colonization or infection with vancomycin-resistant
         <em>
          Enterococcus
         </em>
         and because it has not been associated with clinical benefit [
         <a href="#rid1">
          1,2,79,80
         </a>
         ]. In randomized trials in cancer patients with febrile neutropenia, morbidity and mortality were similar whether or not vancomycin was included in the initial antibiotic regimen [
         <a href="#rid76">
          76,81-83
         </a>
         ]. However, vancomycin may be added to initial therapy in certain patients with complications. (See
         <a class="local">
          'Limited indications for combination therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1150030380">
         <span class="h2">
          Limited indications for combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additions to empiric therapy may be necessary for certain high-risk patients (eg, clinical instability, specific complications)  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef120756" href="/z/d/graphic/120756.html" rel="external">
          table 2B
         </a>
         ). When adding agents to empiric therapy, the combination of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         should be avoided if possible because it has been associated with increased risk of acute kidney injury [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
         Examples of clinical presentations that may warrant broad-spectrum combination empiric therapy are listed below [
         <a href="#rid1">
          1,14,42
         </a>
         ]. In these circumstances, suggested antimicrobial agents should be
         <strong>
          added
         </strong>
         to initial monotherapy.
        </p>
        <p class="headingAnchor" id="H1908797453">
         <span class="h3">
          Signs of sepsis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signs of sepsis include fever, hypotension, unexplained tachycardia and/or widened pulse pressure, mental status changes, and respiratory dysfunction. After consultation with an expert in pediatric critical care for supportive management of septic shock and with an expert in pediatric infectious diseases, the empiric regimen for children with signs of sepsis should be modified according to institutional clinical practice guidelines and clinical features, including previous culture results, concern for multidrug-resistant organisms, and local resistance patterns [
         <a href="#rid86">
          86
         </a>
         ]. Addition of antimicrobial agents with activity against gram-negative bacteria (eg, aminoglycoside or fluoroquinolone) and MRSA (eg,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ),
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         if known to be colonized with or previously infected with vancomycin-resistant organisms) may be warranted. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with a history of multidrug-resistant organisms, we provide broad-spectrum antipseudomonal therapy with
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         or a novel beta-lactamase inhibitor combination (eg,
         <a class="drug drug_pediatric" data-topicid="121356" href="/z/d/drug information/121356.html" rel="external">
          ceftazidime-avibactam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="138674" href="/z/d/drug information/138674.html" rel="external">
          ceftolozane-tazobactam
         </a>
         [
         <a href="#rid87">
          87,88
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with a history of or concern for carbapenem-resistant
         <em>
          Enterobacterales
         </em>
         , we provide broad-spectrum antipseudomonal therapy with a novel beta-lactamase inhibitor combination (eg,
         <a class="drug drug_pediatric" data-topicid="121356" href="/z/d/drug information/121356.html" rel="external">
          ceftazidime-avibactam
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4194473576">
         <span class="h3">
          Gastrointestinal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abdominal pain, rectal pain, perineal inflammation, or blood per rectum – Add anaerobic coverage (eg,
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         ) if not already receiving antibiotics active against anaerobes (eg,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         ) [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         If infection with
         <em>
          C. difficile
         </em>
         is suspected, modifications to the empiric regimen vary with the clinical scenario [
         <a href="#rid90">
          90,91
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsevere initial episode – Add
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         or oral
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe initial episode – Add oral
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent episode – Add oral
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         or oral
         <a class="drug drug_pediatric" data-topicid="126625" href="/z/d/drug information/126625.html" rel="external">
          fidaxomicin
         </a>
        </p>
        <p>
        </p>
        <p>
         The treatment
         <em>
          of C. difficile
         </em>
         in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Treatment and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1966461909">
         <span class="h3">
          Positive blood culture pending identification
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gram-negative bacteria – Change the baseline agent to a carbapenem (eg,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ) if a carbapenem was not chosen initially and add an aminoglycoside
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gram-positive bacteria – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ) (or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         if the patient is known to be colonized with or previously infected with vancomycin-resistant gram-positive organisms)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3990804500">
         <span class="h3">
          Other indications for combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other indications for addition of an agent with additional activity against gram-positive organisms (eg,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ) are listed below [
         <a href="#rid1">
          1,14
         </a>
         ]. Clindamycin should be chosen only if the rates of clindamycin resistance in the cancer center and community center are acceptably low. Linezolid should be chosen only if the child is known to be colonized with or has a history of infection with vancomycin-resistant gram-positive organisms; linezolid should be used with caution because it has been associated with neutropenia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of meningitis or new onset of neurologic signs and symptoms suggestive of meningitis – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ) to broad-spectrum antipseudomonal therapy with
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ; if meropenem is used as the broad-spectrum antipseudomonal agent, use the dose for central nervous system infections: 40 mg/kg IV every eight hours (maximum of 2 g per dose).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographically documented pneumonia – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         if MRSA is suspected  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically suspected central venous catheter-related infection (eg, chills or rigors with infusion through the catheter and cellulitis around the catheter entry or exit site) – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ) to broad-spectrum antipseudomonal therapy [
         <a href="#rid92">
          92
         </a>
         ]. Alternatives to vancomycin include
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , although these agents are not used routinely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin or soft tissue infection at any site – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known colonization with MRSA or penicillin- and cephalosporin-resistant
         <em>
          Streptococcus pneumoniae
         </em>
         or previous history of infection with penicillin-resistant pneumococci – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent intensive chemotherapy associated with a high risk for infection with penicillin-resistant streptococci (eg, viridans streptococci following high-dose
         <a class="drug drug_pediatric" data-topicid="13197" href="/z/d/drug information/13197.html" rel="external">
          cytarabine
         </a>
         ) – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         [
         <a href="#rid14">
          14,93-95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prophylaxis with quinolones during afebrile neutropenia – Add
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         [
         <a href="#rid1">
          1,95-98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1503862523">
         <span class="h1">
          EMPIRIC THERAPY FOR LOW-RISK PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H149867122">
         <span class="h2">
          Inpatient therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with fever and chemotherapy-induced neutropenia who are low risk for serious infection or complications and are not candidates for outpatient therapy are hospitalized for IV broad-spectrum monotherapy with
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef120292" href="/z/d/graphic/120292.html" rel="external">
          table 2A
         </a>
         ) [
         <a href="#rid1">
          1,42
         </a>
         ]. (See
         <a class="local">
          'Broad-spectrum monotherapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1105378869">
         <span class="h2">
          Outpatient therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outpatient management of fever and neutropenia with IV or oral antibiotics may be an option for carefully selected low-risk patients if daily follow-up is ensured [
         <a href="#rid1">
          1,42
         </a>
         ]. Several studies using strict eligibility criteria suggest that outpatient treatment may be safe and appropriate for children at low risk of serious infection [
         <a href="#rid99">
          99-105
         </a>
         ].
        </p>
        <p>
         When children with fever and chemotherapy-induced neutropenia are treated as outpatients, they should receive the first dose of antimicrobial therapy in a clinical or hospital setting and be observed for ≥4 hours before discharge [
         <a href="#rid1">
          1
         </a>
         ]. They should be readmitted for hemodynamic instability, signs and symptoms of new or worsening infection, or, in the absence these, persistent fever (ie, &gt;48 to 96 hours).
        </p>
        <p>
         A systematic review of four randomized trials comparing inpatient and outpatient treatment for children with cancer and low-risk febrile neutropenia [
         <a href="#rid18">
          18,106-108
         </a>
         ] found no clear evidence of different rates of treatment failure, mortality, or adverse drug reactions. However, outpatient treatment in these trials consisted of early discharge after surveillance for 24 to 72 hours rather than exclusive outpatient therapy [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral therapy for select low-risk patients
         </strong>
         –
         <strong>
         </strong>
         Decisions regarding outpatient oral therapy for low-risk children with fever and chemotherapy-induced neutropenia are made on a case by case basis [
         <a href="#rid1">
          1,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Criteria
         </strong>
         – Outpatient oral therapy is an option for children who meet all of the following criteria [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Able to take and absorb oral antibiotics
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Has a caregiver and a telephone
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Live relatively close to their local medical facility in the event of clinical worsening (eg, within one hour)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Able to adhere to daily outpatient follow-up
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patient or caregiver(s) and clinician agree to oral outpatient therapy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Has not been receiving fluoroquinolone prophylaxis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral regimen
         </strong>
         – For low-risk children who receive oral outpatient therapy and have not been receiving fluoroquinolone prophylaxis, we suggest oral empiric therapy with
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         rather than other oral regimens [
         <a href="#rid1">
          1,109-111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although this regimen has not been well-studied in children, it appears to be as effective as IV therapy in low-risk patients [
         <a href="#rid112">
          112
         </a>
         ]. In two randomized trials, the rate of treatment failure and duration of fever, neutropenia, and antimicrobial therapy were similar in patients treated with oral
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         versus IV
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         [
         <a href="#rid109">
          109,111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are few data to guide the choice of outpatient regimen for low-risk children with contraindications to
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         or low-risk children who have been receiving fluoroquinolone prophylaxis. Consultation with an expert in infectious diseases is suggested to optimize the regimen for individual patients. Hospitalization for IV therapy may be necessary.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1454064543">
         <span class="h1">
          ONGOING ANTIMICROBIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Modification of the empiric regimen may be warranted based upon a variety of clinical scenarios, as discussed in the sections below  (
         <a class="graphic graphic_algorithm graphicRef120294" href="/z/d/graphic/120294.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H851683502">
         <span class="h2">
          Clinical worsening or instability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with cancer and febrile neutropenia who worsen or become clinically unstable at any point during antimicrobial therapy should undergo reevaluation for new or worsening sites of infection [
         <a href="#rid1">
          1
         </a>
         ]. If they have been treated in the outpatient setting, they should be admitted for IV therapy.
        </p>
        <p>
         Reevaluation includes thorough examination and imaging or repeat imaging for new or worsening sites of infection, as well as culture, biopsy, or drain of sites of worsening infection (assessing for bacterial, viral, and fungal pathogens). Antimicrobial therapy should be reviewed for adequacy of dosing and spectrum. (See
         <a class="local">
          'History and examination'
         </a>
         above.)
        </p>
        <p>
         For children with hemodynamic instability and no identified source of fever, antimicrobial therapy should be broadened (eg, to increase activity against gram-positive, gram-negative, resistant, and anaerobic bacteria). Appropriately broadened antibacterial therapy may be achieved by changing
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         to
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         , adding
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 5
         </a>
         ), and increasing gram-negative activity by adding an aminoglycoside,
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12949" href="/z/d/drug information/12949.html" rel="external">
          aztreonam
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The addition of antifungal therapy may be warranted for children who remain febrile for ≥96 hours. (See
         <a class="local">
          'Addition of antifungal therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1702283093">
         <span class="h2">
          Documented infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with fever, chemotherapy-induced neutropenia, and documented infection at any point during treatment, antimicrobial therapy is modified according to culture and susceptibility results and/or site of infection [
         <a href="#rid1">
          1
         </a>
         ]. Infection may be documented microbiologically (eg, positive culture) or clinically (eg, cellulitis or pneumonia without isolated pathogen).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical worsening or instability
         </strong>
         – Additional evaluation and management of children with documented infection who worsen clinically or whose clinical status becomes unstable are discussed above. (See
         <a class="local">
          'Clinical worsening or instability'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically stable and improved
         </strong>
         – For those who remain stable and are clinically improved, we tailor the antimicrobial regimen to the infection and continue therapy for 7 to 14 days as appropriate for the infection and until the absolute neutrophil count (ANC) is &gt;500 cells/microL and increasing [
         <a href="#rid1">
          1
         </a>
         ]. Criteria for switching to oral antimicrobial therapy are discussed below. (See
         <a class="local">
          'Switching to oral therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1781450343">
         <span class="h2">
          No documented infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with fever, chemotherapy-induced neutropenia, and no documented infection (ie, unexplained fever) after 48 hours, changes to antimicrobial therapy depend upon the child's clinical status  (
         <a class="graphic graphic_algorithm graphicRef120294" href="/z/d/graphic/120294.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical worsening or instability
         </strong>
         – Evaluation and management of clinical worsening is discussed above. (See
         <a class="local">
          'Clinical worsening or instability'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically stable and afebrile
         </strong>
         –
         <strong>
         </strong>
         For children with chemotherapy-induced neutropenia and no documented infection who are clinically stable and have been afebrile for ≥24 hours, we continue initial empiric therapy until the ANC is &gt;500 cells/microL. However, we discontinue agents with additional gram-positive activity (eg,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ) and/or additional gram-negative activity (eg, aminoglycosides) after 48 hours if they were added to the initial regimen, given the potential harms (eg, nephrotoxicity, colonization or infection with resistant pathogens).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Switching to oral therapy is discussed below. (See
         <a class="local">
          'Switching to oral therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically stable, persistent fever &lt;96 hours (high- or low-risk)
         </strong>
         –
         <strong>
         </strong>
         For children with chemotherapy-induced neutropenia and no documented infection who are clinically stable but remain febrile, we continue initial empiric therapy and daily reevaluation. However, we discontinue agents with additional gram-positive activity (eg,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ) and/or additional gram-negative activity (eg, aminoglycosides) after 48 hours if they were added to the initial regimen, given the potential harms (eg, nephrotoxicity, colonization or infection with resistant pathogens). We adjust the antimicrobial regimen if clinical status changes or an infection is identified. (See
         <a class="local">
          'Reevaluation during treatment'
         </a>
         above and
         <a class="local">
          'Clinical worsening or instability'
         </a>
         above and
         <a class="local">
          'Documented infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically stable, persistent fever for ≥96 hours or recurrent fever (high- or low risk)
         </strong>
         – For children
         <strong>
         </strong>
         with chemotherapy-induced neutropenia and no documented infection who are clinically stable with persistent fever for ≥96 hours despite broad-spectrum empiric antibacterial therapy or who have recurrent fever, we continue empiric antimicrobial therapy and daily reevaluation [
         <a href="#rid1">
          1
         </a>
         ]. Additional management depends upon anticipated bone marrow recovery.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone marrow recovery imminent
         </strong>
         – For clinically stable children with no documented infection, persistent fever for ≥96 hours or recurrent fever, and imminent bone marrow recovery, we modify the antimicrobial regimen only if clinically indicated (eg, examination, laboratory, or imaging studies suggest a new infection).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The duration of antimicrobial therapy is discussed below. (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone marrow recovery not imminent
         </strong>
         – For clinically stable children with no documented infection, persistent fever for ≥96 hours or recurrent fever, and whose bone marrow recovery is not imminent, we generally add antifungal therapy. In addition, we consider noninfectious causes of fever. (See
         <a class="local">
          'Addition of antifungal therapy'
         </a>
         below and
         <a class="local">
          'Noninfectious causes of fever'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2099361517">
         <span class="h2">
          Addition of antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically occult fungal infection must be considered in children with recurrent fever or persistent fever (ie, ≥96 hours) and neutropenia despite empiric antibacterial therapy [
         <a href="#rid1">
          1,42,113
         </a>
         ]. Invasive fungal infection is associated with decreased survival [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – We initiate empiric antifungal therapy in children who have recurrent or persistent fever for ≥96 hours after initiation of empiric broad-spectrum antimicrobial therapy, no identified source of fever, and ANC that is not increasing [
         <a href="#rid1">
          1
         </a>
         ]. In a small, randomized trial, the addition of amphotericin B to antibacterial therapy in children with fever and neutropenia ≥7 days was effective in controlling clinically occult fungal infections and preventing fungal superinfections [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other experts suggest that empiric antifungal therapy may be withheld from such children who are not at increased risk for invasive fungal disease [
         <a href="#rid42">
          42
         </a>
         ] or who do not meet certain prespecified criteria (eg, pulmonary infiltrates, skin lesions suggestive of invasive fungal disease, positive mycology studies) [
         <a href="#rid115">
          115,116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of invasive fungal infection is increased in children with one or more of the following [
         <a href="#rid32">
          32,42,113,114,117-121
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute myeloid leukemia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Relapsed or high-risk acute lymphoblastic leukemia (see
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolonged neutropenia (&gt;10 days)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Highly myelosuppressive chemotherapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-dose glucocorticoid therapy (usually defined as
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         ≥20 mg per day, or ≥2 mg/kg per day for patients weighing &lt;10 kg) for ≥14 days (or equivalent [
         <a href="#rid122">
          122
         </a>
         ])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Allogeneic hematopoietic cell transplant recipient
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Graft-versus-host disease
        </p>
        <p>
        </p>
        <p>
         Support for withholding antifungal therapy for certain children is provided by a trial in which children with persistent high-risk febrile neutropenia were randomly assigned to empiric antifungal therapy or antifungal therapy if, at any time during follow-up, they met prespecified clinical, radiographic, or laboratory criteria (pre-emptive antifungal therapy) [
         <a href="#rid116">
          116
         </a>
         ]. Although only 42 percent of the pre-emptive group received antifungal therapy and the duration of antifungal therapy was shorter (6 versus 11 days), no differences were detected in the rates of invasive fungal disease (12 percent) or mortality related to invasive fungal disease (3 percent).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for fungal infection
         </strong>
         – The suggested evaluation for fungal infection, performed concomitantly with initiation of antifungal therapy, includes [
         <a href="#rid1">
          1,42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ultrasonography and/or computed tomography (CT) of the liver and spleen
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CT of the chest
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CT of the sinuses (in patients with localizing signs or symptoms)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biopsy of any suspicious lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Laboratory-based diagnostic tests for fungal infection include galactomannan, beta-D glucan, and polymerase chain reaction (PCR) assays. These tests have variable sensitivity, specificity, and predictive values [
         <a href="#rid42">
          42,123
         </a>
         ]. None is a reliable predictor of fungal infection in children. Galactomannan is specific for
         <em>
          Aspergillus
         </em>
         molds; results may be negative in children with non-
         <em>
          Aspergillus
         </em>
         fungal infection. Clinical experience with beta-D glucan as a fungal biomarker in children is limited. PCR testing for fungal infection has poor standardization and has poor positive and negative predictive value.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antifungal regimen
         </strong>
         – Appropriate antifungal agents include (one of the following) [
         <a href="#rid1">
          1,42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Amphotericin B
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We prefer lipid formulations of amphotericin B (liposomal amphotericin or amphotericin B complex) to
         <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">
          amphotericin B deoxycholate
         </a>
         . A meta-analysis of four randomized trials [
         <a href="#rid124">
          124-127
         </a>
         ] found lipid formulations of amphotericin B to have similar rates of breakthrough fungal infections but less nephrotoxicity and infusion-related toxicity (liposomal formulations) than conventional amphotericin B [
         <a href="#rid128">
          128
         </a>
         ]. If lipid formulations of amphotericin B are not available, amphotericin B deoxycholate is acceptable [
         <a href="#rid1">
          1,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Echinocandins (eg,
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">
          anidulafungin
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Triazole derivatives (eg,
         <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12997" href="/z/d/drug information/12997.html" rel="external">
          posaconazole
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The duration of antifungal therapy is discussed below. (See
         <a class="local">
          'Total duration'
         </a>
         below.)
        </p>
        <p>
         There is little evidence to guide the choice of antifungal agents for children with febrile neutropenia. Factors that influence the choice of empiric antifungal therapy include antifungal prophylaxis and renal or hepatic dysfunction. For empiric antifungal therapy in children who have been receiving antifungal prophylaxis, we choose an antifungal agent from a different class than the agent used for prophylactic therapy (eg, if they have been receiving an echinocandin, we choose amphotericin B or a triazole). We generally prefer lipid formulations of amphotericin for children with renal dysfunction and
         <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">
          anidulafungin
         </a>
         for children with hepatic and/or renal dysfunction.
        </p>
        <p>
         Data regarding the efficacy and safety of echinocandins and triazole derivatives are limited. In a multicenter randomized trial comparing amphotericin B and
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         in 82 children with persistent fever and neutropenia, rates of response and adverse effects (including infusion-related toxicity and nephrotoxicity) were similar [
         <a href="#rid129">
          129
         </a>
         ]. However, the trial was not powered to detect statistically significant differences. A systematic review comparing amphotericin B with
         <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">
          voriconazole
         </a>
         in cancer patients with neutropenia concluded that amphotericin B is more effective for empiric therapy [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H136157935">
         <span class="h1">
          DURATION OF ANTIMICROBIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H1526597882">
         <span class="h2">
          Total duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The total duration of empiric antimicrobial therapy depends upon the clinical response and myeloid recovery.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibacterial therapy
         </strong>
         – We generally continue antimicrobial therapy until blood cultures have been negative for ≥48 hours, the patient has been afebrile for ≥24 hours, and the ANC is &gt;500 cells/microL and increasing [
         <a href="#rid1">
          1,42,131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, shorter durations of therapy may be appropriate for select low-risk patients [
         <a href="#rid14">
          14,56,132
         </a>
         ]. The 2017 International Pediatric Fever and Neutropenia Guidelines permit low-risk patients who have received IV antibiotics for ≥72 hours, have been afebrile for ≥24 hours, and have no identified source of infection to be discharged from the hospital without antibiotics regardless of marrow recovery if follow-up is ensured [
         <a href="#rid42">
          42
         </a>
         ], as supported by a small retrospective study [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antifungal therapy
         </strong>
         – We usually continue empiric antifungal therapy until resolution of neutropenia in the absence of evidence of invasive fungal infection [
         <a href="#rid1">
          1,42
         </a>
         ]. However, there is little evidence to guide this decision.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4140425054">
         <span class="h2">
          Switching to oral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with adequate gastrointestinal absorption, decisions regarding the switch from IV to oral therapy (and hospital discharge) are individualized according to clinical status. Children who have recurrent fever within 48 hours of initiation of oral therapy should be readmitted to the hospital and managed as high-risk patients [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The following criteria for switching from IV to oral therapy have been safely used in observational studies [
         <a href="#rid12">
          12,18,134-136
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Afebrile ≥24 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically stable and well-appearing
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative blood cultures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local infection (if present) under control
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ANC &gt;100 cell/microL and evidence of bone marrow recovery (ie, sustained increase in platelet count and ANC or absolute phagocyte count [ANC plus absolute monocyte count])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥48 hours of IV therapy
        </p>
        <p>
        </p>
        <p>
         For children with documented infection, the oral regimen is determined by the culture and susceptibility results and/or site of infection. For children with no documented infection who are switched to oral therapy, we use one of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13127" href="/z/d/drug information/13127.html" rel="external">
          Cefixime
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          Ciprofloxacin
         </a>
         (with or without
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         [
         <a href="#rid136">
          136
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          COLONY STIMULATING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether high-risk patients and/or those with predicted prolonged courses of neutropenia (ie, more than seven days) may benefit from the use of granulocyte colony stimulating factors (G-CSF) remains unanswered. Nonetheless, interventional G-CSF may be warranted for certain children with complicated episodes of fever and neutropenia [
         <a href="#rid137">
          137-139
         </a>
         ]. One of the authors of this topic review (PF) routinely provides CSF for children with solid tumors who have fever and neutropenia; the other author of this topic review (NA) provides CSF predominantly in children with chemotherapy-induced neutropenia and decreasing absolute neutrophil count or anticipated prolonged neutropenia.
        </p>
        <p>
         A substantial benefit of initiating CSFs during febrile neutropenia has not been firmly established. In a meta-analysis of three randomized trials, therapeutic CSF (G-CSF or granulocyte monocyte CSF [GM-CSF]) reduced duration of hospitalization by 1.42 days (95% CI 0.62-2.22) compared with placebo [
         <a href="#rid74">
          74
         </a>
         ]. In individual randomized trials, G-CSF and GM-CSF also modestly reduced days of intravenous antibiotics or median time to resolution of neutropenia [
         <a href="#rid140">
          140-142
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2470084363">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110873.html" rel="external">
          "Society guideline links: Neutropenic fever in children with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4164182975">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/89369.html" rel="external">
          "Patient education: Neutropenia and fever in people being treated for cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H184978076">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – We use the following definitions in children with cancer or hematopoietic cell transplant (see
         <a class="local">
          'Definitions'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neutropenia – Absolute neutrophil count (ANC (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         )) &lt;500 cells/microL or an ANC that is expected to decrease to &lt;500 cells/microL during the next 48 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fever – Any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A single oral temperature ≥38.3°C (101°F)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A temperature ≥38°C (100.4°F) for longer than one hour
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Two elevations &gt;38°C (100.4°F) during a 12-hour period
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Rectal temperature measurements should be avoided in neutropenic patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cause of fever
         </strong>
         – Bloodstream infections are the most common cause of fever in children with chemotherapy-induced neutropenia and may be caused by gram-positive organisms, gram-negative organisms, or fungi. (See
         <a class="local">
          'Infectious causes of fever'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Rapid and thorough evaluation is crucial for prompt administration of appropriate empiric antimicrobial therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The history is focused on infection (eg, symptoms, exposures, recent infection or colonization, antimicrobial prophylaxis, central venous catheters and other factors that predispose to infection). (See
         <a class="local">
          'History and examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The physical examination should focus on the sites most commonly infected:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Skin and mucous membranes – Skin folds, nail beds, central catheter sites, perineum (including rectal area), sites of recent procedures
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Sinuses
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oropharynx, including the gums
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Lungs
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Abdomen
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The review of systems and physical examination should be repeated at least daily. (See
         <a class="local">
          'History and examination'
         </a>
         above and
         <a class="local">
          'Reevaluation during treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine laboratory evaluation includes (see
         <a class="local">
          'Routine laboratory and imaging studies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete blood count with differential and platelet count
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electrolytes, creatinine, and blood urea nitrogen
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Liver transaminases and total bilirubin
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Blood cultures
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Additional studies (eg, other cultures, molecular diagnostic assays, imaging) are obtained as clinically indicated (see
         <a class="local">
          'Additional studies as indicated'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Broad-spectrum empiric therapy should be initiated as soon as possible after blood cultures are obtained and always within 60 minutes of triage  (
         <a class="graphic graphic_table graphicRef120292 graphicRef120756" href="/z/d/graphic/120292.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="local">
          'Prompt initiation of antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For high-risk children  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ) with fever and chemotherapy-induced neutropenia in whom there is no suspicion of resistant infection, we recommend initial broad-spectrum monotherapy with an antipseudomonal beta-lactam agent (eg,
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         ) rather than combination therapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Combination therapy is reserved for children with clear indications for additional activity against gram-positive, gram-negative, or anaerobic bacteria  (
         <a class="graphic graphic_table graphicRef120756" href="/z/d/graphic/120756.html" rel="external">
          table 2B
         </a>
         ). (See
         <a class="local">
          'Empiric therapy for high-risk patients'
         </a>
         above and
         <a class="local">
          'Limited indications for combination therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For low-risk children  (
         <a class="graphic graphic_table graphicRef120291" href="/z/d/graphic/120291.html" rel="external">
          table 1
         </a>
         ) with fever and chemotherapy-induced neutropenia, the empiric antimicrobial regimen is influenced by the treatment setting  (
         <a class="graphic graphic_table graphicRef120292" href="/z/d/graphic/120292.html" rel="external">
          table 2A
         </a>
         ). Those who are treated as outpatients should receive the first dose of antimicrobial therapy in the hospital or clinic setting and be observed for ≥4 hours before discharge. (See
         <a class="local">
          'Empiric therapy for low-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ongoing antimicrobial therapy is modified if there is clinical worsening or instability or documented clinical or microbiologic infection. For patients who remain stable and do not have a documented infection, continued antimicrobial therapy is modified according to resolution or persistence of fever and resolution or persistence of neutropenia  (
         <a class="graphic graphic_algorithm graphicRef120294" href="/z/d/graphic/120294.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Ongoing antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We initiate empiric antifungal therapy in children who have recurrent or persistent fever for ≥96 hours after initiation of empiric broad-spectrum antimicrobial therapy, no identified source of fever, and ANC that is not increasing. Options for antifungal therapy in children include amphotericin B, echinocandins (eg,
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">
          anidulafungin
         </a>
         ), or a triazole derivative (eg,
         <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12997" href="/z/d/drug information/12997.html" rel="external">
          posaconazole
         </a>
         ). (See
         <a class="local">
          'Addition of antifungal therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We generally continue antimicrobial therapy until blood cultures have been negative for ≥48 hours, the patient has been afebrile for ≥24 hours, and the ANC is &gt;500 cells/microL and increasing. (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. 2012. https://www.nice.org.uk/guidance/cg151 (Accessed on November 06, 2018).
         </li>
         <li class="breakAll">
          Wolff LJ, Ablin AR, Altman AJ, Johnson FL. The management of fever. In: Supportive care of children with cancer: Current therapy and guidelines from the Children's Cancer Group, Ablin AR (Ed), Johns Hopkins University Press, Baltimore 1997. p.23.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012.
          </a>
         </li>
         <li class="breakAll">
          St. Jude Children's Research Hospital Fever and neutropenia. Available at: https://www.stjude.org/treatment/patient-resources/caregiver-resources/patient-family-education-sheets/prevent-control-infection/fever-and-neutropenia.html (Accessed on January 02, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lekshminarayanan A, Bhatt P, Linga VG, et al. National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014. J Pediatr 2018; 202:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allaway Z, Phillips RS, Thursky KA, Haeusler GM. Nonneutropenic fever in children with cancer: A scoping review of management and outcome. Pediatr Blood Cancer 2019; 66:e27634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Foster C, Vázquez N, et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 1997; 19:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orgel E, Ji L, Pastor W, Schore RJ. Infectious morbidity by catheter type in neutropenic children with cancer. Pediatr Infect Dis J 2014; 33:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996; 14:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agyeman P, Kontny U, Nadal D, et al. A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study. Pediatr Infect Dis J 2014; 33:e219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haeusler GM, De Abreu Lourenco R, Clark H, et al. Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia. J Pediatric Infect Dis Soc 2021; 10:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stergiotis M, Ammann RA, Droz S, et al. Pediatric fever in neutropenia with bacteremia-Pathogen distribution and in vitro antibiotic susceptibility patterns over time in a retrospective single-center cohort study. PLoS One 2021; 16:e0246654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed N, El-Mahallawy HA, Ahmed IA, et al. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatr Blood Cancer 2007; 49:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roguin A, Kasis I, Ben-Arush MW, et al. Fever and neutropenia in children with malignant disease. Pediatr Hematol Oncol 1996; 13:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agyeman P, Aebi C, Hirt A, et al. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 2011; 30:e114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doganis D, Asmar B, Yankelevich M, et al. Predictive factors for blood stream infections in children with cancer. Pediatr Hematol Oncol 2013; 30:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heston SM, Young RR, Hong H, et al. Microbiology of Bloodstream Infections in Children After Hematopoietic Stem Cell Transplantation: A Single-Center Experience Over Two Decades (1997-2017). Open Forum Infect Dis 2020; 7:ofaa465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999; 21:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aquino VM, Pappo A, Buchanan GR, et al. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 1995; 14:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palazzi DL. The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia: the importance of risk stratification. Pediatr Infect Dis J 2011; 30:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake JG, Weiner LM, Milstone AM, et al. Pathogen Distribution and Antimicrobial Resistance Among Pediatric Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2011-2014. Infect Control Hosp Epidemiol 2018; 39:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TJ, Pizzo PA. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol 1988; 42:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzo PA, Walsh TJ. Fungal infections in the pediatric cancer patient. Semin Oncol 1990; 17:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009; 48:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramphal R, Grant RM, Dzolganovski B, et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsimpardi K, Papadakis V, Pangalis A, et al. Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer 2006; 14:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindblom A, Bhadri V, Söderhäll S, et al. Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol 2010; 47:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres JP, Labraña Y, Ibañez C, et al. Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia. Pediatr Infect Dis J 2012; 31:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suryadevara M, Tabarani CM, Bartholoma N, et al. Nasopharyngeal detection of respiratory viruses in febrile neutropenic children. Clin Pediatr (Phila) 2012; 51:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres JP, De la Maza V, Kors L, et al. Respiratory Viral Infections and Coinfections in Children With Cancer, Fever and Neutropenia: Clinical Outcome of Infections Caused by Different Respiratory Viruses. Pediatr Infect Dis J 2016; 35:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher BT, Danziger-Isakov L, Sweet LR, et al. A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. J Pediatric Infect Dis Soc 2018; 7:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerdeira Barreiro N, Santiago-García B, Casas I, et al. Detection of Respiratory Viruses in the Clinical Outcome of Children With Fever and Neutropenia. Pediatr Infect Dis J 2020; 39:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes LL, Torres SR, Garnica M, et al. Oral status of patients submitted to autologous hematopoietic stem cell transplantation. Support Care Cancer 2014; 22:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol 2017; 35:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19:3415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann RA, Hirt A, Lüthy AR, Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003; 41:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doganis D, Asmar B, Yankelevich M, et al. How many sources should be cultured for the diagnosis of a blood stream infection in children with cancer? Pediatr Hematol Oncol 2013; 30:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999; 18:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson JL. Sensitivity of a blood culture drawn through a single lumen of a multilumen, long-term, indwelling, central venous catheter in pediatric oncology patients. J Pediatr Hematol Oncol 2002; 24:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklin JA, Gaur AH, Shenep JL, et al. In situ diagnosis of central venous catheter-related bloodstream infection without peripheral blood culture. Pediatr Infect Dis J 2004; 23:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez L, Ethier MC, Phillips B, et al. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review. Support Care Cancer 2012; 20:3261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaassen IL, de Haas V, van Wijk JA, et al. Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 2011; 56:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca EV, Pardo CA, Linares A, et al. Clinical Characteristics and Outcomes of a Cohort of Pediatric Oncohematologic Patients With COVID-19 Infection in the City of Bogotá, Colombia. Pediatr Infect Dis J 2021; 40:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renoult E, Buteau C, Turgeon N, et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korones DN. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neemann K, Yonts AB, Qiu F, et al. Blood Cultures for Persistent Fever in Neutropenic Pediatric Patients Are of Low Diagnostic Yield. J Pediatric Infect Dis Soc 2016; 5:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006; 28:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 2012; 7:e38300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alali M, David MZ, Danziger-Isakov LA, et al. Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation. Pediatr Infect Dis J 2020; 39:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakim H, Flynn PM, Srivastava DK, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2010; 29:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salstrom JL, Coughlin RL, Pool K, et al. Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Pediatr Blood Cancer 2015; 62:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 2014; 14:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher M, Hodgkiss H, Zhang S, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer 2013; 60:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014; 58:3799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haeusler GM, Mechinaud F, Daley AJ, et al. Antibiotic-resistant Gram-negative bacteremia in pediatric oncology patients--risk factors and outcomes. Pediatr Infect Dis J 2013; 32:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shono Y, van den Brink MRM. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage? Blood Adv 2017; 1:2325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shono Y, Docampo MD, Peled JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 2016; 8:339ra71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simms-Waldrip TR, Sunkersett G, Coughlin LA, et al. Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients. Biol Blood Marrow Transplant 2017; 23:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilinski J, Robak K, Peric Z, et al. Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study. Biol Blood Marrow Transplant 2016; 22:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber D, Jenq RR, Peled JU, et al. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017; 23:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Viola M, Guéant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 2007; 146:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson PD, Lehrnbecher T, Phillips R, et al. Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials. J Clin Oncol 2016; 34:2054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013; :CD003038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beyar-Katz O, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2017; 6:CD003914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sano H, Kobayashi R, Suzuki D, et al. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamma PD, Turnbull AE, Harris AD, et al. Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients. JAMA Pediatr 2013; 167:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karandikar MV, Milliren CE, Zaboulian R, et al. Limiting Vancomycin Exposure in Pediatric Oncology Patients With Febrile Neutropenia May Be Associated With Decreased Vancomycin-Resistant Enterococcus Incidence. J Pediatric Infect Dis Soc 2020; 9:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991; 163:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook KM, Gillon J, Grisso AG, et al. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study. J Pediatric Infect Dis Soc 2019; 8:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021; 72:e169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlowsky JA, Lob SH, Raddatz J, et al. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis 2021; 72:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perruccio K, Rosaria D'Amico M, Baretta V, et al. Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections. Pediatr Infect Dis J 2022; 41:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diorio C, Robinson PD, Ammann RA, et al. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol 2018; 36:3162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotiropoulos SV, Jackson MA, Woods GM, et al. Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J 1989; 8:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paganini H, Staffolani V, Zubizarreta P, et al. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer 2003; 39:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 2004; 39:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986; 81:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003; 97:1775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivas-Ruiz R, Villasis-Keever M, Miranda-Novales G, et al. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event. Cochrane Database Syst Rev 2019; 3:CD009031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paolino J, Mariani J, Lucas A, et al. Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Pediatr Blood Cancer 2019; 66:e27679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson TJ, Napper R, Haeusler GM, et al. Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics. Arch Dis Child 2023; 108:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 2012; 59:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orme LM, Babl FE, Barnes C, et al. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. Pediatr Blood Cancer 2014; 61:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 2004; 22:3784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Swaroop C, Agarwala S, et al. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009; 31:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagol AR, Castro Junior CG, Martins MC, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J) 2009; 85:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung L, Manji A, Beyene J, et al. Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. Pediatr Infect Dis J 2012; 31:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villarroel M, Avilés CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation. Pediatr Infect Dis J 2010; 29:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi R, Hori D, Sano H, et al. Risk Factors for Invasive Fungal Infection in Children and Adolescents With Hematologic and Malignant Diseases: A 10-year Analysis in a Single Institute in Japan. Pediatr Infect Dis J 2018; 37:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Groll AH. Pre-emptive versus empirical antifungal therapy in immunocompromised children. Lancet Child Adolesc Health 2019; 3:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother 2018; 73:2860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117:e711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999; 42:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. J Pediatric Infect Dis Soc 2018; 7:191.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.72.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Robinson PD, Fisher BT, et al. Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis 2016; 63:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000; 22:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev 2014; :CD004707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell ME, Friedman DL, Dulek DE, et al. Safety of discharge for children with cancer and febrile neutropenia off antibiotics using absolute neutrophil count threshold values as a surrogate marker for adequate bone marrow recovery. Pediatr Blood Cancer 2018; 65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Stanescu A, Kühl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002; 30:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aquino VM, Buchanan GR, Tkaczewski I, Mustafa MM. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 1997; 28:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994; 74:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson J, Mehra S, Hersh AL, et al. Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. J Pediatric Infect Dis Soc 2021; 10:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 1998; 157:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003; :CD003039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997; 15:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2005; 45:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riikonen P, Saarinen UM, Mäkipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994; 13:197.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6051 Version 61.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10694551" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10694551" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17968824" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30029861" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30724005" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nonneutropenic fever in children with cancer: A scoping review of management and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329461" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Therapy-induced alterations in host defense in children receiving therapy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24263218" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infectious morbidity by catheter type in neutropenic children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7058815" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8616774" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622040" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Predicting the risk of bacteremia in childen with fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644403" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Etiology and clinical course of febrile neutropenia in children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24618935" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32267508" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33577566" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pediatric fever in neutropenia with bacteremia-Pathogen distribution and in vitro antibiotic susceptibility patterns over time in a retrospective single-center cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17366527" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8940733" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fever and neutropenia in children with malignant disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21394050" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23521175" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Predictive factors for blood stream infections in children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33209953" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Microbiology of Bloodstream Infections in Children After Hematopoietic Stem Cell Transplantation: A Single-Center Experience Over Two Decades (1997-2017).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10598661" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Infections in children with cancer: a continued need for the comprehensive physical examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7746697" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The changing epidemiology of bacteremia in neutropenic children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21915020" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia: the importance of risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29249216" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pathogen Distribution and Antimicrobial Resistance Among Pediatric Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2011-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3060000" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2191445" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fungal infections in the pediatric cancer patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9242529" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19267655" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Phaeohyphomycosis in a tertiary care cancer center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21319281" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Invasive fungal infections in pediatric oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848881" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16270193" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056482" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Respiratory viruses, a common microbiological finding in neutropenic children with fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22565292" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22893186" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Nasopharyngeal detection of respiratory viruses in febrile neutropenic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27518750" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Respiratory Viral Infections and Coinfections in Children With Cancer, Fever and Neutropenia: Clinical Outcome of Infections Caused by Different Respiratory Viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29106589" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32091498" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Detection of Respiratory Viruses in the Clinical Outcome of Children With Fever and Neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23975228" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Oral status of patients submitted to autologous hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28459614" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11454890" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14515382" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570564" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : How many sources should be cultured for the diagnosis of a blood stream infection in children with cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10391191" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11902747" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sensitivity of a blood culture drawn through a single lumen of a multilumen, long-term, indwelling, central venous catheter in pediatric oncology patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247598" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : In situ diagnosis of central venous catheter-related bloodstream infection without peripheral blood culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22544224" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20949597" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pyuria is absent during urinary tract infections in neutropenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33956754" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical Characteristics and Outcomes of a Cohort of Pediatric Oncohematologic Patients With COVID-19 Infection in the City of Bogotá, Colombia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15266405" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15481080" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27199474" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Blood Cultures for Persistent Fever in Neutropenic Pediatric Patients Are of Low Diagnostic Yield.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11902738" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231680" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17023827" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22693615" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5216294" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32176187" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996816" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risk prediction in pediatric cancer patients with fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25663663" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24716604" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Time to antibiotics and outcomes in cancer patients with febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23417978" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24752269" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23838774" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Antibiotic-resistant Gram-negative bacteremia in pediatric oncology patients--risk factors and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296882" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27194729" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28192251" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26900084" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28232086" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19422028" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310050" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27022114" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23813455" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28577308" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27873451" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23921724" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7639408" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31603472" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Limiting Vancomycin Exposure in Pediatric Oncology Patients With Febrile Neutropenia May Be Associated With Decreased Vancomycin-Resistant Enterococcus Incidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1510394" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2019772" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10530436" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973124" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590376" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33106864" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrumβ-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32246147" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36375099" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20034345" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29462280" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30216124" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2594450" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763218" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332520" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3050517" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578362" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3526884" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648546" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10391572" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112678" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12655535" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30887505" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30916887" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36600323" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22271702" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24604835" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365075" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684522" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10423464" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20016870" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22189521" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616763" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30408007" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Risk Factors for Invasive Fungal Infection in Children and Adolescents With Hematologic and Malignant Diseases: A 10-year Analysis in a Single Institute in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31204310" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Pre-emptive versus empirical antifungal therapy in immunocompromised children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30010931" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16804435" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Fungal infections in children with cancer: a prospective, multicenter surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15750444" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16533892" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10546484" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28549148" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28549148" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27567122" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Galactomannan,β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10072411" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864055" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Use of amphotericin B colloidal dispersion in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332329" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709879" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20166083" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20431381" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24563222" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/380336" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Duration of empiric antibiotic therapy in granulocytopenic patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29115709" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Safety of discharge for children with cancer and febrile neutropenia off antibiotics using absolute neutrophil count threshold values as a surrogate marker for adequate bone marrow recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11876510" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024515" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8004575" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32092134" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11841397" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Haematopoietic growth factors in children with neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9877032" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917942" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Colony stimulating factors for chemotherapy induced febrile neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9060560" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806544" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8177627" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
